# Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

> **NCT00003007** · PHASE2 · COMPLETED · sponsor: **University of Tennessee**

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **BIOLOGICAL:** sargramostim
- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone
- **DRUG:** melphalan
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00003007
- **Lead sponsor:** University of Tennessee
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-07
- **Primary completion:** —
- **Final completion:** 2004-01
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003007, "Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00003007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*